Table of Contents
Executive Summary
- Chart 1. Rilutek Revenues Split between Seven Major Markets and Remaining
Regions in 2006
- Chart 2. Rilutek Revenues ($m) by Country in the Seven Major Markets
- Chart 3. Overall Forecast for Rilutek in Seven Major Markets ($m),2007-2012
- Table 1. Overall Forecast for Rilutek in Seven Major Markets ($m),2007-2012
1. Amyotrophic Lateral Sclerosis
- 1.1 Introducing Amyotrophic Lateral Sclerosis
- 1.2 The Progression of ALS
- 1.3 Risk Factors of ALS
- 1.4 The Diagnosis of ALS
- 1.5 The Demographic Impact of ALS
- Chart 4. Percentage distribution of ALS
Chapter 2. Treatment of ALS
- 2.1 What are the Treatment Options for ALS?
- 2.1.2 Rilutek (riluzole)
- 2.1.3Symptom Management with other Pharmacological Agents
- 2.1.4 Neurontin (Gabapentin)
- Chart 5. Teva (Neurontin) Revenue Forecast,2007-2012
- Chart 6. Pfizers (Neurontin) Revenue Forecast,2007-2012
- Chart 7. Actavis (Neurontin) Revenue Forecast, 2007-2012
- Chart 8. Apotex (Neurontin) Revenue Forecast,2007-2012
- Chart 9. Pharmascience (Neurontin) Revenue Forecast, 2007-2012
- 2.1.5 Topamax (Topiramate)
- Chart 10. Topamax Revenue 2003-2006
Chapter 3. Medical Devices used in ALS
- 3.1 Medical Devices and Future care in ALS
- 3.1.2 Air-way clearing Assistive Devices Technology
- Table 2. Airway Clearance Medical Devices,Used during ALS patient care
- 3.1.3 Cost of Medical Devices in ALS
- 3.1.4 Will use of devices affect market growth?
- 3.1.5 Significant Mergers and Acquisition of Me dical Device Technologies
- Table 3. M&A Medical Device and Technology Deals,2006
Chapter 4. Research into ALS treatments
- 4.1 Investor Focus on ALS Research
- 4.1.1 Potential candidates for ALS
- 4.1.2 The Antibiotic Minocycline may have a Role in ALS Treatment
- 4.1.3 Cox-2 (Nimesulide)
- 4.1.4 The Role of Apoptosis in ALS
- 4.1.5 Biological Markers for ALS
- 4.1.6 Gene Research in ALS
- 4.1.7 Gene Therapy
- 4.1.8 Gene Therapy Delivery Vehicle
Chapter 5. Future developments
- 5.1 Creatine Monohydrate
- 5.3 Xaliproden Hydrochloride to Regenerate NF
- Table 4. Failed Drugs and Present ALS Clinical Trials Pipeline
Chapter 6. Rilutek Regional Markets Analysis
- 6.1 US Market Outlook
- Chart 11. US Market Growth Rate 2002-2003
- 6.1.2 Market Share Dominated by US
- Chart 12. US Health Budget Allocation in comparison to Other Regions
- Chart 13. Population With and Without Health Insurance Coverage in the
US
- Chart 14. Split of Health Insurance Providers in the US
- 6.1.3 US Expenditure on Pharmaceutical products
- Chart.15 US Pharmaceutical Market Revenue 2005-2006
- 6.1.4 US Rilutek Market Analysis
- 6.1.5 Rilutek Market Share
- Chart.16 Rilutek Revenue 2005-2006
- Chart 17. US Combined Rilutek Revenues 2003-2006
- Chart 18. US Rilutek Revenue 2003-2006
- 6.1.6 Rising Medicare Part D to Affect Rilutek
- 6.1.7 US Dominates ALS Research
- 6.1.8 US Rilutek Revenue Forecast 2007-2012
- Chart 19. US Rilutek Revenue Forecast 2007-2012
- 6.1.9 Drivers and Restraints of the US Rilutek Market
- 6.1.10 Drivers
- 6.1.11 Restraints
- 6.2 Japan Market Outlook
- Chart 20. Japan Pharmaceutical Revenues ($bn) 2004-2006
- 6.2.2 Japan' s Healthcare System
- 6.2.3 Medical Expenditure in Japan
- Chart 21. Japan Medical Expenditure 1990s (JPY Trillions)
- 6.2.4 Japan Healthcare Strategic Reform
- 6.2.5 Strategic long-term care insurance care reforms
- 6.2.6 Japan Pharmaceutical Market Analysis
- 6.2.7 Rilutek Market Performance and Analysis
- Chart 22. Japan Rilutek Combined Revenue 2003-2006
- Chart 23. Japan Rilutek Revenue 2003-2006 in the two market sectors
- Chart 24. Japan Rilutek Revenue Forecast 2007-2012
- 6.2.8 Drivers and Restraints
- 6.2.9 Drivers
- 6.2.10 Restraints
- 6.3 France Pharmaceutical Market Outlook
- Chart 25. France' s Pharmaceutical Market Revenues ($bn) 2002-2006
- 6.3.1 Healthcare System
- 6.3.2 France Health and Medical Expenditure
- 6.3.3 Rilutek Market Performance and Analysis
- Chart 26. Rilutek Combined Revenue in France,2003-2006
- Chart 27. Rilutek Retail and Hospital Revenues in France, 2003-2006
- Chart 28. France Rilutek Revenue Forecast,2007-2012
- 6.3.4 Rilutek Market Drivers and Restraints
- 6.3.4.1 Market Drivers
- 6.3.4.2 Market Restraints
- 6.4 Germany Pharmaceutical Outlook
- Chart 29. Germany' s Pharmaceutical Revenues ($bn), 2002-2006
- 6.4.1 Germany Healthcare System
- 6.4.2 Pharmaceutical Sector Reforms
- 6.4.3 Germany Rilutek Market Performance and Analysis
- Chart 30. Germany Rilutek Combined Revenues,2003-2006
- Chart 31. Germany Rilutek Retail and Hospital Revenues,2003-2006
- Chart 32. Germany Rilutek Retail Revenues by company in 2006
- Chart 33. Germany Rilutek Hospital Revenues by company in 2006
- Chart 34. Germany Rilutek Revenue Forecast, 2007-2012
- 6.4.4 Rilutek Market Drivers and Restraints
- 6.4.5 Market Drivers
- 6.4.6 Market Restraints
- 6.5 Italy Pharmaceutical Outlook
- Chart 33. Italy' s Pharmaceutical Revenues ($bn), 2004-2006
- 6.5.1 Italy' s Healthcare System and Reforms
- 6.5.2 Italy Rilutek Market Performance and Analysis
- 6.5.3 Prevalence of ALS in Italy
- Chart 34. Italy' s Rilutek Revenues ($m), 2004-2006
- 6.5.4 Italy Rilutek Revenue Forecast,2007-2012
- Chart 35. Italy Rilutek Revenue Forecast,2007-2012
- 6.5.5 Rilutek Market Drivers and Restraints
- 6.5.6 Market Drivers
- 6.5.7 Market Restraints
- 6.6 UK Pharmaceutical Outlook
- Chart 36. UK Global Pharmaceutical Revenues ($b),2002-2006
- 6.6.1 UK Healthcare system
- 6.6.2 UK NHS and Department of Health
- 6.6.3 NHS and Private Healthcare
- 6.6.4 UK Healthcare Insurance Policies
- 6.6.5 Current NHS Prescription Volumes
- 6.6.7 Dominance of Generic Market
- 6.6.8 UK Rilutek Market Performance and Analysis
- Chart 37. UK Rilutek Combined Revenues ($m), 2003-2006
- Chart 38. UK Rilutek Split Revenues ($m), 2003-2006
- Chart 39. UK Rilutek Revenues Forecast,2007-2012
- 6.6.9 Rilutek Market Drivers and Restraints
- 6.6.10 Market Drivers
- 6.6.11 Market Restraints
- 6.7 Spain Pharmaceutical Outlook
- Chart 40. Spain Pharmaceutical Revenues ($bn), 2002-2006
- 6.7.1 Spain' s Rilutek Market Performance Analysis
- Chart 41. Spain' s Combined Riluitek Revenues ($m), 2003-2006
- Chart 42. Spain' s Riluitek Revenue Forecast,2006-2012
- 6.7. Rilutek Market Drivers and Restraints
- 6.7.1 Market Drivers
- 6.7.2 Market Restraints
Chapter 7. Conclusion
Chapter 8.
- 8. SWOT Analysis on Amyotrophic Lateral Sclerosis Market
- 8.1 Strengths
- 8.2 Weaknesses
- 8.3 Opportunities
- 8.4 Threats
Organisations mentioned in this report:
- Abbott Laboratories
- Actavis
- Advanced Respiratory
- Aircast
- Allergan
- American Medical Instruments
- American Medical Systems
- Amyotrophic Lateral Sclerosis Association (ALSA) Amyotrophic Lateral
- Sclerosis Therapy Development Institute (ALS TDI) AngioDynamics Angiotech
- Pharmaceuticals Animas Ann Neurology Apollo Apotex Avanir Avicena Baxter
- Healthcare Biomet Blackstone Group Blackstone Medical Boston Scientific C.
- R. Bard Celgene Cephalon Coloplast Compex Technologies Confluent Surgical
- Conor Medsystems CytRX DHD Healthcare Disc-O-Tech Medical Technologies DJ
- Orthopedics Dymedso Electromed Encore Medical ExonHit Therapeutics Getinge
- Goldman Sachs Capital Partners Guidant Huntleigh Technology Impax Inamed
- Integra Life Sciences Irish Medicines Board (IMB) Johnson & Johnson Knopp
- Neurosciences Kohlberg Kravis Roberts & Co TPG Kyphon Laserscope Medegen
- Medical Products Medsystems Medtech Mentor Merck Miltex Instruments
Muscular
- Dystrophy Association (MDA) National Institute of Health (NIH) Northeast
- Amyotrophic Lateral Sclerosis Consortium(NEALS) Orthofix International
- Ortho-McNeill Pari Respiratory Pfizer Pharmascience RITA Medical Systems
- Sanofi-Aventis Scandipharm St. Francis Medical Technologies Teva Texas
- Pacific Group Themis Trophos Tyco Healthcare Venetec International
|
Related Report
|
View Cart
